Grape King Bio Ltd (1707) - Net Assets
Based on the latest financial reports, Grape King Bio Ltd (1707) has net assets worth NT$11.64 Billion TWD (≈ $366.66 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$14.49 Billion ≈ $456.50 Million USD) and total liabilities (NT$2.85 Billion ≈ $89.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 1707 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$11.64 Billion |
| % of Total Assets | 80.32% |
| Annual Growth Rate | 9.96% |
| 5-Year Change | 47.78% |
| 10-Year Change | 179.43% |
| Growth Volatility | 9.08 |
Grape King Bio Ltd - Net Assets Trend (2002–2024)
This chart illustrates how Grape King Bio Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Grape King Bio Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Grape King Bio Ltd (2002–2024)
The table below shows the annual net assets of Grape King Bio Ltd from 2002 to 2024. For live valuation and market cap data, see Grape King Bio Ltd (1707) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$11.79 Billion ≈ $371.47 Million |
+1.38% |
| 2023-12-31 | NT$11.63 Billion ≈ $366.41 Million |
+4.39% |
| 2022-12-31 | NT$11.14 Billion ≈ $351.00 Million |
+6.82% |
| 2021-12-31 | NT$10.43 Billion ≈ $328.58 Million |
+30.72% |
| 2020-12-31 | NT$7.98 Billion ≈ $251.37 Million |
+6.79% |
| 2019-12-31 | NT$7.47 Billion ≈ $235.37 Million |
+7.75% |
| 2018-12-31 | NT$6.93 Billion ≈ $218.44 Million |
+9.57% |
| 2017-12-31 | NT$6.33 Billion ≈ $199.37 Million |
+9.42% |
| 2016-12-31 | NT$5.78 Billion ≈ $182.19 Million |
+37.05% |
| 2015-12-31 | NT$4.22 Billion ≈ $132.94 Million |
+13.53% |
| 2014-12-31 | NT$3.72 Billion ≈ $117.10 Million |
+15.40% |
| 2013-12-31 | NT$3.22 Billion ≈ $101.47 Million |
+17.46% |
| 2012-12-31 | NT$2.74 Billion ≈ $86.39 Million |
+10.95% |
| 2011-12-31 | NT$2.47 Billion ≈ $77.86 Million |
+9.36% |
| 2010-12-31 | NT$2.26 Billion ≈ $71.20 Million |
+8.87% |
| 2009-12-31 | NT$2.08 Billion ≈ $65.40 Million |
+19.01% |
| 2008-12-31 | NT$1.74 Billion ≈ $54.95 Million |
-1.63% |
| 2007-12-31 | NT$1.77 Billion ≈ $55.86 Million |
+4.38% |
| 2006-12-31 | NT$1.70 Billion ≈ $53.52 Million |
+6.16% |
| 2005-12-31 | NT$1.60 Billion ≈ $50.42 Million |
+1.33% |
| 2004-12-31 | NT$1.58 Billion ≈ $49.75 Million |
+6.43% |
| 2003-12-31 | NT$1.48 Billion ≈ $46.75 Million |
+1.56% |
| 2002-12-31 | NT$1.46 Billion ≈ $46.03 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Grape King Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 400492900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$4.00 Billion | 39.83% |
| Common Stock | NT$1.48 Billion | 14.73% |
| Other Comprehensive Income | NT$1.71 Billion | 17.04% |
| Other Components | NT$2.86 Billion | 28.40% |
| Total Equity | NT$10.06 Billion | 100.00% |
Grape King Bio Ltd Competitors by Market Cap
The table below lists competitors of Grape King Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Central Emporium Group Stocks Co Ltd
SHG:600280
|
$525.05 Million |
|
Gulf Oil Lubricants India Limited
NSE:GULFOILLUB
|
$525.32 Million |
|
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
|
$525.38 Million |
|
Man Infraconstruction Limited
NSE:MANINFRA
|
$525.39 Million |
|
Canadian Banc Corp
TO:BK
|
$525.03 Million |
|
HCM II Acquisition Corp. Unit
NASDAQ:HONDU
|
$525.00 Million |
|
Meridian Mining UK Societas
TO:MNO
|
$524.93 Million |
|
Optotech Corp
TW:2340
|
$524.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grape King Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,978,299,000 to 10,055,699,000, a change of 77,400,000 (0.8%).
- Net income of 1,448,299,000 contributed positively to equity growth.
- Dividend payments of 1,022,148,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,713,475,000.
- Other factors decreased equity by 2,062,226,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$1.45 Billion | +14.4% |
| Dividends Paid | NT$1.02 Billion | -10.16% |
| Other Comprehensive Income | NT$1.71 Billion | +17.04% |
| Other Changes | NT$-2.06 Billion | -20.51% |
| Total Change | NT$- | 0.78% |
Book Value vs Market Value Analysis
This analysis compares Grape King Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.67x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.83x to 1.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | NT$12.74 | NT$112.50 | x |
| 2007-12-31 | NT$13.20 | NT$112.50 | x |
| 2008-12-31 | NT$12.93 | NT$112.50 | x |
| 2009-12-31 | NT$14.88 | NT$112.50 | x |
| 2010-12-31 | NT$15.94 | NT$112.50 | x |
| 2011-12-31 | NT$17.08 | NT$112.50 | x |
| 2012-12-31 | NT$18.69 | NT$112.50 | x |
| 2013-12-31 | NT$21.19 | NT$112.50 | x |
| 2014-12-31 | NT$23.46 | NT$112.50 | x |
| 2015-12-31 | NT$26.14 | NT$112.50 | x |
| 2016-12-31 | NT$35.13 | NT$112.50 | x |
| 2017-12-31 | NT$38.05 | NT$112.50 | x |
| 2018-12-31 | NT$41.97 | NT$112.50 | x |
| 2019-12-31 | NT$45.19 | NT$112.50 | x |
| 2020-12-31 | NT$48.39 | NT$112.50 | x |
| 2021-12-31 | NT$60.57 | NT$112.50 | x |
| 2022-12-31 | NT$64.20 | NT$112.50 | x |
| 2023-12-31 | NT$66.91 | NT$112.50 | x |
| 2024-12-31 | NT$67.41 | NT$112.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grape King Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.40%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.98%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.52x
- Recent ROE (14.40%) is below the historical average (19.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 2.90% | 4.01% | 0.43x | 1.70x | NT$-103.68 Million |
| 2003 | 1.92% | 2.37% | 0.52x | 1.56x | NT$-119.89 Million |
| 2004 | 5.15% | 6.51% | 0.51x | 1.55x | NT$-76.57 Million |
| 2006 | 9.07% | 10.10% | 0.60x | 1.50x | NT$-15.49 Million |
| 2007 | 10.52% | 10.63% | 0.67x | 1.47x | NT$9.00 Million |
| 2008 | 9.77% | 7.79% | 0.82x | 1.54x | NT$-3.82 Million |
| 2009 | 19.58% | 13.44% | 0.88x | 1.65x | NT$185.56 Million |
| 2010 | 20.61% | 13.03% | 1.03x | 1.54x | NT$220.15 Million |
| 2011 | 21.27% | 12.54% | 1.09x | 1.55x | NT$250.68 Million |
| 2012 | 25.43% | 13.42% | 1.19x | 1.59x | NT$375.49 Million |
| 2013 | 30.15% | 14.79% | 1.22x | 1.67x | NT$558.57 Million |
| 2014 | 30.69% | 15.00% | 1.17x | 1.75x | NT$635.39 Million |
| 2015 | 30.24% | 14.51% | 0.84x | 2.48x | NT$703.83 Million |
| 2016 | 26.97% | 14.12% | 0.96x | 1.99x | NT$815.97 Million |
| 2017 | 26.02% | 14.40% | 0.95x | 1.90x | NT$832.42 Million |
| 2018 | 22.61% | 14.11% | 0.86x | 1.86x | NT$722.36 Million |
| 2019 | 31.40% | 20.98% | 0.81x | 1.84x | NT$1.32 Billion |
| 2020 | 28.61% | 20.67% | 0.70x | 1.98x | NT$1.23 Billion |
| 2021 | 21.67% | 19.88% | 0.70x | 1.56x | NT$1.05 Billion |
| 2022 | 22.67% | 20.88% | 0.69x | 1.57x | NT$1.21 Billion |
| 2023 | 14.56% | 13.66% | 0.69x | 1.55x | NT$454.90 Million |
| 2024 | 14.40% | 12.98% | 0.73x | 1.52x | NT$442.73 Million |
Industry Comparison
This section compares Grape King Bio Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,648,336,444
- Average return on equity (ROE) among peers: 6.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Grape King Bio Ltd (1707) | NT$11.64 Billion | 2.90% | 0.25x | $525.05 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $1.58 Billion | 9.37% | 0.81x | $343.42 Million |
| Maywufa Co Ltd (1731) | $2.01 Billion | 8.19% | 0.34x | $90.66 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.23 Billion | 6.44% | 0.25x | $505.73 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $596.05 Million | -6.44% | 0.88x | $1.83 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $830.77 Million | 11.25% | 0.43x | $49.64 Million |
| LIWANLI Innovation Co Ltd (3054) | $783.51 Million | 0.65% | 0.06x | $167.70 Million |
| YungShin Global Holding Corp (3705) | $9.98 Billion | 11.71% | 0.38x | $466.59 Million |
| TTY Biopharm Co Ltd (4105) | $6.51 Billion | 17.35% | 0.52x | $581.27 Million |
| Phytohealth Corp (4108) | $332.05 Million | 0.00% | 0.04x | $76.66 Million |
About Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics… Read more